<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35406750</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Neurotoxic Astrocytes Directly Converted from Sporadic and Familial ALS Patient Fibroblasts Reveal Signature Diversities and miR-146a Theragnostic Potential in Specific Subtypes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1186</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11071186</ELocationID><Abstract><AbstractText>A lack of stratification methods in patients with amyotrophic lateral sclerosis (ALS) is likely implicated in therapeutic failures. Regional diversities and pathophysiological abnormalities in astrocytes from mice with SOD1 mutations (mSOD1-ALS) can now be explored in human patients using somatic cell reprogramming. Here, fibroblasts from four sporadic (sALS) and three mSOD1-ALS patients were transdifferentiated into induced astrocytes (iAstrocytes). ALS iAstrocytes were neurotoxic toward HB9-GFP mouse motor neurons (MNs) and exhibited subtype stratification through GFAP, CX43, Ki-67, miR-155 and miR-146a expression levels. Up- (two cases) and down-regulated (three cases) miR-146a values in iAstrocytes were recapitulated in their secretome, either free or as cargo in small extracellular vesicles (sEVs). We previously showed that the neuroprotective phenotype of depleted miR-146 mSOD1 cortical astrocytes was reverted by its mimic. Thus, we tested such modulation in the most miR-146a-depleted patient-iAstrocytes (one sALS and one mSOD1-ALS). The miR-146a mimic in ALS iAstrocytes counteracted their reactive/inflammatory profile and restored miR-146a levels in sEVs. A reduction in lysosomal activity and enhanced synaptic/axonal transport-related genes in NSC-34 MNs occurred after co-culture with miR-146a-modulated iAstrocytes. In summary, the regulation of miR-146a in depleted ALS astrocytes may be key in reestablishing their normal function and in restoring MN lysosomal/synaptic dynamic plasticity in disease sub-groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>C&#xe1;tia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sequeira</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Likhite</LastName><ForeName>Shibi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennys</LastName><ForeName>Cassandra N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolb</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-8503-8459</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH 43214, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaz</LastName><ForeName>Ana R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-3418-3269</Identifier><AffiliationInfo><Affiliation>Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Sciences and Medicines, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaspar</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brites</LastName><ForeName>Dora</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3024-9777</Identifier><AffiliationInfo><Affiliation>Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Sciences and Medicines, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>JS-BRC-1215-20017</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C542542">MIRN146 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020258" MajorTopicYN="Y">Neurotoxicity Syndromes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">astrocyte-mediated neurotoxicity</Keyword><Keyword MajorTopicYN="N">fibroblast-transdifferentiated astrocytes</Keyword><Keyword MajorTopicYN="N">inflammatory-associated miRNAs</Keyword><Keyword MajorTopicYN="N">miR-146a modulation</Keyword><Keyword MajorTopicYN="N">mutant SOD1 (mSOD1)</Keyword><Keyword MajorTopicYN="N">patient phenotype subtypes</Keyword><Keyword MajorTopicYN="N">small extracellular vesicles (sEVs)</Keyword><Keyword MajorTopicYN="N">sporadic ALS (sALS)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35406750</ArticleId><ArticleId IdType="pmc">PMC8997588</ArticleId><ArticleId IdType="doi">10.3390/cells11071186</ArticleId><ArticleId IdType="pii">cells11071186</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rojas P., Ramirez A.I., Fernandez-Albarral J.A., Lopez-Cuenca I., Salobrar-Garcia E., Cadena M., Elvira-Hurtado L., Salazar J.J., de Hoz R., Ramirez J.M. Amyotrophic Lateral Sclerosis: A Neurodegenerative Motor Neuron Disease with Ocular Involvement. Front. Neurosci. 2020;14:566858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544921</ArticleId><ArticleId IdType="pubmed">33071739</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiryaki E., Horak H.A. ALS and other motor neuron diseases. Continuum (Minneap. Minn.) 2014;20:1185&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">25299277</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Katyal N., Govindarajan R. Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement. Front. Neurol. 2017;8:521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626834</ArticleId><ArticleId IdType="pubmed">29033893</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017;9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Komine O. The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 2018;126:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M., Harlan B.A., Killoy K.M., Vargas M.R. Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis. Curr. Pharm. Des. 2017;23:5010&#x2013;5021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740017</ArticleId><ArticleId IdType="pubmed">28641533</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., Barbeito L., Yamanaka K. Phenotypic heterogeneity of astrocytes in motor neuron disease. Clin. Exp. Neuroimmunol. 2018;9:225&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6282976</ArticleId><ArticleId IdType="pubmed">30555538</ArticleId></ArticleIdList></Reference><Reference><Citation>Stifani S. Taking Cellular Heterogeneity Into Consideration When Modeling Astrocyte Involvement in Amyotrophic Lateral Sclerosis Using Human Induced Pluripotent Stem Cells. Front. Cell. Neurosci. 2021;15:707861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8485040</ArticleId><ArticleId IdType="pubmed">34602979</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal A., Vogel T. Different Flavors of Astrocytes: Revising the Origins of Astrocyte Diversity and Epigenetic Signatures to Understand Heterogeneity after Injury. Int. J. Mol. Sci. 2021;22:6867. doi: 10.3390/ijms22136867.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22136867</ArticleId><ArticleId IdType="pmc">PMC8268487</ArticleId><ArticleId IdType="pubmed">34206710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajroud-Driss S., Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS) Biochim. Biophys. Acta. 2015;1852:679&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">25193032</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M., DeJesus-Hernandez M., Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: Can we learn from other noncoding repeat expansion disorders? Curr. Opin. Neurol. 2012;25:689&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923493</ArticleId><ArticleId IdType="pubmed">23160421</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdynski M., Miszta P., Safranow K., Andersen P.M., Morita M., Filipek S., Zekanowski C., Kuzma-Kozakiewicz M. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci. Rep. 2022;12:103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8742055</ArticleId><ArticleId IdType="pubmed">34996976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.X., Xu H.F., Wang P.S., Yang X.X., Wu Z.Y., Li H.F. SOD1 Mutation Spectrum and Natural History of ALS Patients in a 15-Year Cohort in Southeastern China. Front. Genet. 2021;12:746060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8551486</ArticleId><ArticleId IdType="pubmed">34721532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q., Zhou Q., Chen Y., Ou R., Cao B., Xu Y., Yang J., Shang H.F. Analysis of SOD1 mutations in a Chinese population with amyotrophic lateral sclerosis: A case-control study and literature review. Sci. Rep. 2017;7:44606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349524</ArticleId><ArticleId IdType="pubmed">28291249</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips A.M., Hester M.E., Miranda C.J., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K., Ferraiuolo L., Miranda C.J., Likhite S., McElroy S., Renusch S., Ditsworth D., Lagier-Tourenne C., Smith R.A., Ravits J., et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc. Natl. Acad. Sci. USA. 2014;111:829&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Cunha C., Nascimento F., Ribeiro J.A., Vaz A.R., Brites D. Cortical neurotoxic astrocytes with early ALS pathology and miR-146a deficit replicate gliosis markers of symptomatic SOD1G93A mouse model. Mol. Neurobiol. 2019;56:2137&#x2013;2158.</Citation><ArticleIdList><ArticleId IdType="pubmed">29995256</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Amarilla P., Olivera-Bravo S., Trias E., Cragnolini A., Martinez-Palma L., Cassina P., Beckman J., Barbeito L. Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2011;108:18126&#x2013;18131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207668</ArticleId><ArticleId IdType="pubmed">22010221</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz S.H., Pinto S., Sebasti&#xe3;o A.M., Brites D. Astrocytes in Amyotrophic Lateral Sclerosis. Exon Publications; Brisbane, Australia: 2021. Chapter 3.</Citation></Reference><Reference><Citation>Johann S. Astrocytes Pathology in ALS: A Potential Therapeutic Target? Curr. Pharm. Des. 2017;23:5022&#x2013;5036.</Citation><ArticleIdList><ArticleId IdType="pubmed">28619000</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Robberecht W., Van Den Bosch L. Modelling amyotrophic lateral sclerosis: Progress and possibilities. Dis. Model. Mech. 2017;10:537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelaini S., Cochrane A., Margariti A. Direct reprogramming of adult cells: Avoiding the pluripotent state. Stem Cells Cloning. 2014;7:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931695</ArticleId><ArticleId IdType="pubmed">24627642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto N., Dos Santos Souza C., Shaw A.C., Bell S.M., Myszczynska M.A., Powers S., Meyer K., Castelli L.M., Karyka E., Mortiboys H., et al. Directly converted astrocytes retain the ageing features of the donor fibroblasts and elucidate the astrocytic contribution to human CNS health and disease. Aging Cell. 2021;20:e13281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811849</ArticleId><ArticleId IdType="pubmed">33314575</ArticleId></ArticleIdList></Reference><Reference><Citation>Roybon L., Lamas N.J., Garcia A.D., Yang E.J., Sattler R., Lewis V.J., Kim Y.A., Kachel C.A., Rothstein J.D., Przedborski S., et al. Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. Cell Rep. 2013;4:1035&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229657</ArticleId><ArticleId IdType="pubmed">23994478</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio A., Bilican B., Barmada S.J., Ando D.M., Zhao C., Siller R., Burr K., Haghi G., Story D., Nishimura A.L., et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc. Natl. Acad. Sci. USA. 2013;110:4697&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607024</ArticleId><ArticleId IdType="pubmed">23401527</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksanen M., Petersen A.J., Naumenko N., Puttonen K., Lehtonen S., Gubert Olive M., Shakirzyanova A., Leskela S., Sarajarvi T., Viitanen M., et al. PSEN1 mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer&#x2019;s disease. Stem Cell Rep. 2017;9:1885&#x2013;1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785689</ArticleId><ArticleId IdType="pubmed">29153989</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C., Apolloni S., Parisi C. MicroRNAs: Newcomers into the ALS picture. CNS Neurol. Disord. Drug Targets. 2015;14:194&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S., Lu H.C. microRNAs in Neurodegeneration: Current Findings and Potential Impacts. J. Alzheimers Dis Parkinsonism. 2018;8:420. doi: 10.4172/2161-0460.1000420.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2161-0460.1000420</ArticleId><ArticleId IdType="pmc">PMC5976447</ArticleId><ArticleId IdType="pubmed">29862137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chugh P., Dittmer D.P. Potential pitfalls in microRNA profiling. Wiley Interdiscip. Rev. RNA. 2012;3:601&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597218</ArticleId><ArticleId IdType="pubmed">22566380</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahamtan A., Teymoori-Rad M., Nakstad B., Salimi V. Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment. Front. Immunol. 2018;9:1377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6026627</ArticleId><ArticleId IdType="pubmed">29988529</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn S.R., O&#x2019;Neill L.A. A trio of microRNAs that control Toll-like receptor signalling. Int. Immunol. 2011;23:421&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">21652514</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivieri F., Rippo M.R., Procopio A.D., Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. Front. Genet. 2013;4:121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693036</ArticleId><ArticleId IdType="pubmed">23805154</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C., Santos C., Gomes C., Fernandes A., Correia A.M., Sebasti&#xe3;o A.M., Vaz A.R., Brites D. Downregulated glia interplay and increased miRNA-155 as promising markers to track ALS at an early stage. Mol. Neurobiol. 2018;55:4207&#x2013;4224.</Citation><ArticleIdList><ArticleId IdType="pubmed">28612258</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D. Regulatory function of microRNAs in microglia. Glia. 2020;68:1631&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pubmed">32463968</ArticleId></ArticleIdList></Reference><Reference><Citation>Halushka M.K., Fromm B., Peterson K.J., McCall M.N. Big Strides in Cellular MicroRNA Expression. Trends Genet. 2018;34:165&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834366</ArticleId><ArticleId IdType="pubmed">29361313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell E., Taylor M.A. Functional roles for exosomal microRNAs in the tumour microenvironment. Comput. Struct. Biotechnol. J. 2017;15:8&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5109280</ArticleId><ArticleId IdType="pubmed">27872688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Sequeira C., Barbosa M., Cunha C., Vaz A.R., Brites D. Astrocyte regional diversity in ALS includes distinct aberrant phenotypes with common and causal pathological processes. Exp. Cell. Res. 2020;395:112209.</Citation><ArticleIdList><ArticleId IdType="pubmed">32739211</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke B.E., Taha D.M., Tyzack G.E., Patani R. Regionally encoded functional heterogeneity of astrocytes in health and disease: A perspective. Glia. 2021;69:20&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">32749770</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Jedrychowski M.P., Cialic R., Krasemann S., Murugaiyan G., Fanek Z., Greco D.J., Wu P.M., Doykan C.E., Kiner O., et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 2015;77:75&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa M., Gomes C., Sequeira C., Goncalves-Ribeiro J., Pina C.C., Carvalho L.A., Moreira R., Vaz S.H., Vaz A.R., Brites D. Recovery of depleted miR-146a in ALS cortical astrocytes reverts cell aberrancies and prevents paracrine pathogenicity on microglia and motor neurons. Front. Cell. Dev. Biol. 2021;9:634355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103001</ArticleId><ArticleId IdType="pubmed">33968923</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada I., Gabrielli M., Turola E., Iorio A., D&#x2019;Arrigo G., Parolisi R., De Luca M., Pacifici M., Bastoni M., Lombardi M., et al. Glia-to-neuron transfer of miRNAs via extracellular vesicles: A new mechanism underlying inflammation-induced synaptic alterations. Acta Neuropatho.l. 2018;135:529&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5978931</ArticleId><ArticleId IdType="pubmed">29302779</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S., Cunha C., Barbosa M., Vaz A.R., Brites D. Exosomes from NSC-34 cells transfected with hSOD1-G93A are enriched in miR-124 and drive alterations in microglia phenotype. Front. Neurosci. 2017;11:273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434170</ArticleId><ArticleId IdType="pubmed">28567000</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes A., Ribeiro A.R., Monteiro M., Garcia G., Vaz A.R., Brites D. Secretome from SH-SY5Y APPswe cells trigger time-dependent CHME3 microglia activation phenotypes, ultimately leading to miR-21 exosome shuttling. Biochimie. 2018;155:67&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29857185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravnik-Glavac M., Glavac D. Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2020;21:1714. doi: 10.3390/ijms21051714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21051714</ArticleId><ArticleId IdType="pmc">PMC7084402</ArticleId><ArticleId IdType="pubmed">32138249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennys C.N., Sierra-Delgado J.A., Ray S.S., Hartlaub A.M., Roussel F.S., Rodriguez Y., Meyer K. In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes. J. Vis. Exp. 2021;172:e62016. doi: 10.3791/62016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/62016</ArticleId><ArticleId IdType="pubmed">34180877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hester M.E., Song S., Miranda C.J., Eagle A., Schwartz P.H., Kaspar B.K. Two factor reprogramming of human neural stem cells into pluripotency. PLoS ONE. 2009;4:e7044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739296</ArticleId><ArticleId IdType="pubmed">19763260</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopford M.J., Allen S.P., Ferraiuolo L. A High-throughput and Pathophysiologically Relevant Astrocyte-motor Neuron Co-culture Assay for Amyotrophic Lateral Sclerosis Therapeutic Discovery. Bio. Protoc. 2019;9:e3353. doi: 10.21769/BioProtoc.3353.</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/BioProtoc.3353</ArticleId><ArticleId IdType="pmc">PMC6774773</ArticleId><ArticleId IdType="pubmed">31579294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C., Gomes C., Vaz A.R., Brites D. Exploring new inflammatory biomarkers and pathways during LPS-induced M1 polarization. Mediators Inflamm. 2016;2016:6986175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209629</ArticleId><ArticleId IdType="pubmed">28096568</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldeira C., Oliveira A.F., Cunha C., Vaz A.R., Falc&#xe3;o A.S., Fernandes A., Brites D. Microglia change from a reactive to an age-like phenotype with the time in culture. Front. Cell. Neurosci. 2014;8:152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4040822</ArticleId><ArticleId IdType="pubmed">24917789</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz A.R., Cunha C., Gomes C., Schmucki N., Barbosa M., Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol. Neurobiol. 2015;51:864&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">24848512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucchia M., Merwin S.J., Re D.B., Kariya S. Limitations and Challenges in Modeling Diseases Involving Spinal Motor Neuron Degeneration in Vitro. Front. Cell. Neurosci. 2018;12:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845677</ArticleId><ArticleId IdType="pubmed">29559895</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho R., Sances S., Gowing G., Amoroso M.W., O&#x2019;Rourke J.G., Sahabian A., Wichterle H., Baloh R.H., Sareen D., Svendsen C.N. ALS disrupts spinal motor neuron maturation and aging pathways within gene co-expression networks. Nat. Neurosci. 2016;19:1256&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003654</ArticleId><ArticleId IdType="pubmed">27428653</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M.R., Johnson J.A. Astrogliosis in amyotrophic lateral sclerosis: Role and therapeutic potential of astrocytes. Neurotherapeutics. 2010;7:471&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967019</ArticleId><ArticleId IdType="pubmed">20880509</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C., Hur J., Lunn J.S., Paez-Colasante X., Bender D.E., Yung R., Sakowski S.A., Feldman E.L. Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol. Cell. Neurosci. 2016;71:34&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761498</ArticleId><ArticleId IdType="pubmed">26704906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew M.V., Vinters H.V. Astrocytes: Biology and pathology. Acta Neuropathol. 2010;119:7&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799634</ArticleId><ArticleId IdType="pubmed">20012068</ArticleId></ArticleIdList></Reference><Reference><Citation>Almad A.A., Doreswamy A., Gross S.K., Richard J.P., Huo Y., Haughey N., Maragakis N.J. Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia. 2016;64:1154&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5635605</ArticleId><ArticleId IdType="pubmed">27083773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziff O.J., Clarke B.E., Taha D.M., Crerar H., Luscombe N.M., Patani R. Meta-analysis of human and mouse ALS astrocytes reveals multi-omic signatures of inflammatory reactive states. Genome Res. 2022;32:71&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8744676</ArticleId><ArticleId IdType="pubmed">34963663</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger A., Ben-Dor I., Ottolenghi M., Turetsky T., Gil Y., Sweetat S., Perez L., Belzer V., Casden N., Steiner D., et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine. 2019;50:274&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921360</ArticleId><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Madill M., McDonagh K., Ma J., Vajda A., McLoughlin P., O&#x2019;Brien T., Hardiman O., Shen S. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol. Brain. 2017;10:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470320</ArticleId><ArticleId IdType="pubmed">28610619</ArticleId></ArticleIdList></Reference><Reference><Citation>Walgrave H., Zhou L., De Strooper B., Salta E. The promise of microRNA-based therapies in Alzheimer&#x2019;s disease: Challenges and perspectives. Mol. Neurodegener. 2021;16:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8572071</ArticleId><ArticleId IdType="pubmed">34742333</ArticleId></ArticleIdList></Reference><Reference><Citation>Foggin S., Mesquita-Ribeiro R., Dajas-Bailador F., Layfield R. Biological Significance of microRNA Biomarkers in ALS-Innocent Bystanders or Disease Culprits? Front. Neurol. 2019;10:578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579821</ArticleId><ArticleId IdType="pubmed">31244752</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C., Arisi I., D&#x2019;Ambrosi N., Storti A.E., Brandi R., D&#x2019;Onofrio M., Volonte C. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013;4:e959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877562</ArticleId><ArticleId IdType="pubmed">24336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman H.M., Ghonaim G.A., Gharib S.M., Chopra H., Farag A.K., Hassanin M.H., Nagah A., Emad-Eldin M., Hashem N.E., Yahya G., et al. Exosomes in Alzheimer&#x2019;s Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics. Int. J. Mol. Sci. 2021;22:10794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8509246</ArticleId><ArticleId IdType="pubmed">34639135</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X., Wang Y., Huang Y., Zhang H., Lu H., Zheng J.C. Exosomal miRNAs in central nervous system diseases: Biomarkers, pathological mediators, protective factors and therapeutic agents. Prog. Neurobiol. 2019;183:101694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323939</ArticleId><ArticleId IdType="pubmed">31542363</ArticleId></ArticleIdList></Reference><Reference><Citation>de Abreu R.C., Ramos C.V., Becher C., Lino M., Jesus C., da Costa Martins P.A., Martins P.A.T., Moreno M.J., Fernandes H., Ferreira L. Exogenous loading of miRNAs into small extracellular vesicles. J. Extracell. Vesicles. 2021;10:e12111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8329988</ArticleId><ArticleId IdType="pubmed">34377372</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi S., Israel S., Nagy C., Turecki G. The emerging role of exosomes in mental disorders. Transl. Psychiatry. 2019;9:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438960</ArticleId><ArticleId IdType="pubmed">30923321</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A., Zurolo E., Prabowo A., Fluiter K., Spliet W.G., van Rijen P.C., Gorter J.A., Aronica E. MicroRNA-146a: A key regulator of astrocyte-mediated inflammatory response. PLoS ONE. 2012;7:e44789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3441440</ArticleId><ArticleId IdType="pubmed">23028621</ArticleId></ArticleIdList></Reference><Reference><Citation>Muroi M., Tanamoto K. IRAK-1-mediated negative regulation of Toll-like receptor signaling through proteasome-dependent downregulation of TRAF6. Biochim. Biophys. Acta. 2012;1823:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">22033459</ArticleId></ArticleIdList></Reference><Reference><Citation>van Loo G., Beyaert R. Negative regulation of NF-kappaB and its involvement in rheumatoid arthritis. Arthritis Res. Ther. 2011;13:221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218875</ArticleId><ArticleId IdType="pubmed">21639951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero D., La Salvia S., Giannini M., Crippa V., Gagliardi S., Bernuzzi S., Diamanti L., Ceroni M., Pansarasa O., Poletti A., et al. Pathological Proteins Are Transported by Extracellular Vesicles of Sporadic Amyotrophic Lateral Sclerosis Patients. Front. Neurosci. 2018;12:487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060258</ArticleId><ArticleId IdType="pubmed">30072868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q.Y., Wen T., Wu P., Jia R., Zhang R., Dang J. Exosomal Proteins and miRNAs as Mediators of Amyotrophic Lateral Sclerosis. Front. Cell Dev. Biol. 2021;9:718803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461026</ArticleId><ArticleId IdType="pubmed">34568332</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz A.R., Vizinha D., Morais H., Colaco A.R., Loch-Neckel G., Barbosa M., Brites D. Overexpression of miR-124 in motor neurons plays a key role in ALS pathological processes. Int. J. Mol. Sci. 2021;22:6128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201298</ArticleId><ArticleId IdType="pubmed">34200161</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques C.R., Pereira-Sousa J., Teixeira F.G., Sousa R.A., Teixeira-Castro A., Salgado A.J. Mesenchymal stem cell secretome protects against alpha-synuclein-induced neurodegeneration in a Caenorhabditis elegans model of Parkinson&#x2019;s disease. Cytotherapy. 2021;23:894&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">34059421</ArticleId></ArticleIdList></Reference><Reference><Citation>Giunti D., Marini C., Parodi B., Usai C., Milanese M., Bonanno G., Kerlero de Rosbo N., Uccelli A. Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation. Sci. Rep. 2021;11:1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814007</ArticleId><ArticleId IdType="pubmed">33462263</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe J.R., Bear M.F., Golshani P., Klann E., Lipton S.A., Mucke L., Sahin M., Silva A.J. The mouse as a model for neuropsychiatric drug development. Curr. Biol. 2018;28:R909&#x2013;R914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8163022</ArticleId><ArticleId IdType="pubmed">30205056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R.M. All (animal) models (of neurodegeneration) are wrong. Are they also useful? J. Exp. Med. 2018;215:2955&#x2013;2958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279414</ArticleId><ArticleId IdType="pubmed">30459159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhartiya D. Clinical translation of stem cells for regenerative medicine. Circ. Res. 2019;124:840&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">30870131</ArticleId></ArticleIdList></Reference><Reference><Citation>Haake K., Ackermann M., Lachmann N. Concise review: Towards the clinical translation of induced pluripotent stem cell-derived blood cells-ready for take-off. Stem Cells Transl. Med. 2019;8:332&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431684</ArticleId><ArticleId IdType="pubmed">30585439</ArticleId></ArticleIdList></Reference><Reference><Citation>Galieva L.R., James V., Mukhamedshina Y.O., Rizvanov A.A. Therapeutic potential of extracellular vesicles for the treatment of nerve disorders. Front. Neurosci. 2019;13:163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411850</ArticleId><ArticleId IdType="pubmed">30890911</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Yang R., Xu B., Fu J., Qu X., Li L., Dai M., Tan C., Chen H., Wang X. miR-155 and miR-146a collectively regulate meningitic Escherichia coli infection-mediated neuroinflammatory responses. J. Neuroinflammation. 2021;18:114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8120916</ArticleId><ArticleId IdType="pubmed">33985523</ArticleId></ArticleIdList></Reference><Reference><Citation>Koval E.D., Shaner C., Zhang P., du Maine X., Fischer K., Tay J., Chau B.N., Wu G.F., Miller T.M. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum. Mol. Genet. 2013;22:4127&#x2013;4135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781640</ArticleId><ArticleId IdType="pubmed">23740943</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters R., Subham S., Pacelli S., Modaresi S., Chakravarti A.R., Paul A. Development of microRNA-146a-enriched stem cell secretome for wound-healing applications. Mol. Pharm. 2019;16:4302&#x2013;4312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260687</ArticleId><ArticleId IdType="pubmed">31398053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2011;70:349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">21487309</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudi V., Gai L., Herder V., Tejedor L.S., Kipp M., Amor S., Suhs K.W., Hansmann F., Beineke A., Baumgartner W., et al. Synaptophysin is a reliable marker for axonal damage. J. Neuropathol. Exp. Neurol. 2017;76:109&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">28177496</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore K., Carrico Z., Alfonso S., Marino M., Koymans K., Kessels H.W., Malinow R. PSD-95 protects synapses from &#x3b2;-amyloid. Cell. Rep. 2021;35:109194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237704</ArticleId><ArticleId IdType="pubmed">34077732</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebasti&#xe3;o A.M., Rei N., Ribeiro J.A. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Front. Pharmacol. 2018;9:267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911503</ArticleId><ArticleId IdType="pubmed">29713276</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos K.J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol. Dis. 2017;105:283&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K., Katsuno M., Kawai K., Ishigaki S., Tanaka F., Sobue G. Disruption of axonal transport in motor neuron diseases. Int. J. Mol. Sci. 2012;13:1225&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269748</ArticleId><ArticleId IdType="pubmed">22312314</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69:5&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueffner R., Zach N., Bronfeld M., Norel R., Atassi N., Balagurusamy V., Di Camillo B., Chio A., Cudkowicz M., Dillenberger D., et al. Stratification of amyotrophic lateral sclerosis patients: A crowdsourcing approach. Sci. Rep. 2019;9:690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345935</ArticleId><ArticleId IdType="pubmed">30679616</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine H., Patani R. The translational potential of human induced pluripotent stem cells for clinical neurology: The translational potential of hiPSCs in neurology. Cell. Biol. Toxicol. 2017;33:129&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325844</ArticleId><ArticleId IdType="pubmed">27915387</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxler L., Edenhofer F., Mertens J. Next-generation disease modeling with direct conversion: A new path to old neurons. FEBS Lett. 2019;593:3316&#x2013;3337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907729</ArticleId><ArticleId IdType="pubmed">31715002</ArticleId></ArticleIdList></Reference><Reference><Citation>Caiazzo M., Giannelli S., Valente P., Lignani G., Carissimo A., Sessa A., Colasante G., Bartolomeo R., Massimino L., Ferroni S., et al. Direct conversion of fibroblasts into functional astrocytes by defined transcription factors. Stem Cell Rep. 2015;4:25&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297873</ArticleId><ArticleId IdType="pubmed">25556566</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D., Kato T., Kushner P.D. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J. Neurosci. Res. 1994;38:336&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D., Cordera S., Cavalla P., Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 1996;139:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian K., Huang H., Peterson A., Hu B., Maragakis N.J., Ming G.L., Chen H., Zhang S.C. Sporadic ALS astrocytes induce neuronal degeneration in vivo. Stem Cell Rep. 2017;8:843&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390239</ArticleId><ArticleId IdType="pubmed">28366455</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Barnwell J., Al-Chalabi A., Eisen A. Young-onset amyotrophic lateral sclerosis: Historical and other observations. Brain. 2012;135:2883&#x2013;2891.</Citation><ArticleIdList><ArticleId IdType="pubmed">22661746</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi P., Rodriguez-Muela N., Klim J.R., de Boer A.S., Agrawal S., Sandoe J., Lopes C.S., Ogliari K.S., Williams L.A., Shear M., et al. Reactive astrocytes promote ALS-like degeneration and intracellular protein aggregation in human motor neurons by disrupting autophagy through TGF-beta1. Stem Cell Rep. 2017;9:667&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5549875</ArticleId><ArticleId IdType="pubmed">28712846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunze A., Lengacher S., Dirren E., Aebischer P., Magistretti P.J., Renaud P. Astrocyte-neuron co-culture on microchips based on the model of SOD mutation to mimic ALS. Integr. Biol. 2013;5:964&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">23695230</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshii Y., Otomo A., Pan L., Ohtsuka M., Hadano S. Loss of glial fibrillary acidic protein marginally accelerates disease progression in a SOD1(H46R) transgenic mouse model of ALS. Neurosci. Res. 2011;70:321&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">21453731</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffrey J., D&#x2019;Cunha H., Suzuki M. Blood Level of Glial Fibrillary Acidic Protein (GFAP) Does not Correlate With Disease Progression in a Rat Model of Familial ALS (SOD1(G93A) Transgenic) Front. Neurol. 2018;9:954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6246740</ArticleId><ArticleId IdType="pubmed">30487774</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C., Galea E., Lakatos A., O&#x2019;Callaghan J.P., Petzold G.C., Serrano-Pozo A., Steinhauser C., Volterra A., Carmignoto G., Agarwal A., et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 2021;24:312&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicario N., Zappala A., Calabrese G., Gulino R., Parenti C., Gulisano M., Parenti R. Connexins in the Central Nervous System: Physiological Traits and Neuroprotective Targets. Front. Physiol. 2017;8:1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741605</ArticleId><ArticleId IdType="pubmed">29326598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tribulova N., Dupont E., Soukup T., Okruhlicova L., Severs N.J. Sex differences in connexin-43 expression in left ventricles of aging rats. Physiol. Res. 2005;54:705&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">16351499</ArticleId></ArticleIdList></Reference><Reference><Citation>Stauffer B.L., Sobus R.D., Sucharov C.C. Sex differences in cardiomyocyte connexin43 expression. J. Cardiovasc. Pharmacol. 2011;58:32&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136750</ArticleId><ArticleId IdType="pubmed">21753256</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcianna A., Myszczynska M.A., Castelli L.M., O&#x2019;Neill B., Kim Y., Talbot J., Nyberg S., Nyamali I., Heath P.R., Stopford M.J., et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine. 2019;40:626&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413467</ArticleId><ArticleId IdType="pubmed">30711519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchison E.R., Kawamoto E.M., Taub D.D., Lal A., Abdelmohsen K., Zhang Y., Wood W.H., 3rd, Lehrmann E., Camandola S., Becker K.G., et al. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia. 2013;61:1018&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624280</ArticleId><ArticleId IdType="pubmed">23650073</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L., Cheng Z., Zhang J., Li R., Zhao P., Fu Z., You Y. Hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008;1236:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">18710654</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegoraro V., Merico A., Angelini C. Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration. J. Neurol. Sci. 2017;380:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5598142</ArticleId><ArticleId IdType="pubmed">28870590</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes J.R., Custodia C.M., Silva R.J., de Almeida L.P., Pedroso de Lima M.C., Cardoso A.L. Early miR-155 upregulation contributes to neuroinflammation in Alzheimer&#x2019;s disease triple transgenic mouse model. Hum. Mol. Genet. 2014;23:6286&#x2013;6301.</Citation><ArticleIdList><ArticleId IdType="pubmed">24990149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sison S.L., Patitucci T.N., Seminary E.R., Villalon E., Lorson C.L., Ebert A.D. Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy. Hum. Mol. Genet. 2017;26:3409&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pubmed">28637335</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R., Wyles M., Heath P.R., Kazoka M., Wollff H., Shaw P.J., Kirby J. Small RNA Sequencing of Sporadic Amyotrophic Lateral Sclerosis Cerebrospinal Fluid Reveals Differentially Expressed miRNAs Related to Neural and Glial Activity. Front. Neurosci. 2017;11:731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767269</ArticleId><ArticleId IdType="pubmed">29375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasca E., Pegoraro V., Merico A., Angelini C. Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin. Neuropathol. 2016;35:22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26588026</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M., Hu R., Runtsch M.C., Kagele D.A., Mosbruger T.L., Tolmachova T., Seabra M.C., Round J.L., Ward D.M., O&#x2019;Connell R.M. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat. Commun. 2015;6:7321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557301</ArticleId><ArticleId IdType="pubmed">26084661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara D., Pasetto L., Bonetto V., Basso M. Role of Extracellular Vesicles in Amyotrophic Lateral Sclerosis. Front. Neurosci. 2018;12:574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107782</ArticleId><ArticleId IdType="pubmed">30174585</ArticleId></ArticleIdList></Reference><Reference><Citation>Pashangzadeh S., Motallebnezhad M., Vafashoar F., Khalvandi A., Mojtabavi N. Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases. Front. Immunol. 2021;12:669382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137895</ArticleId><ArticleId IdType="pubmed">34025671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilahi E., Tarr T., Papp G., Griger Z., Sipka S., Zeher M. Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear cells of patients with Sjogren&#x2019;s syndrome. Immunol. Lett. 2012;141:165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">22033216</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y.F., Shu R., Jiang S.Y., Song Z.C., Guo Q.M., Dong J.C., Lin Z.K. miRNA-146 negatively regulates the production of pro-inflammatory cytokines via NF-kappaB signalling in human gingival fibroblasts. J. Inflamm. 2014;11:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297434</ArticleId><ArticleId IdType="pubmed">25598707</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidotti G., Scarlata C., Brambilla L., Rossi D. Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foe? Cells. 2021;10:518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8000008</ArticleId><ArticleId IdType="pubmed">33804386</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla L., Martorana F., Guidotti G., Rossi D. Dysregulation of Astrocytic HMGB1 Signaling in Amyotrophic Lateral Sclerosis. Front. Neurosci. 2018;12:622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123379</ArticleId><ArticleId IdType="pubmed">30210286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Zhang C., Liu L., A X., Chen B., Li Y., Du J. Macrophage-Derived mir-155-Containing Exosomes Suppress Fibroblast Proliferation and Promote Fibroblast Inflammation during Cardiac Injury. Mol. Ther. 2017;25:192&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363311</ArticleId><ArticleId IdType="pubmed">28129114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L.S., Fregeac J., Bole-Feysot C., Cagnard N., Iyer A., Anink J., Aronica E., Alibeu O., Nitschke P., Colleaux L. Role of miR-146a in neural stem cell differentiation and neural lineage determination: Relevance for neurodevelopmental disorders. Autism. 2018;9:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6011198</ArticleId><ArticleId IdType="pubmed">29951184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C., Thielen P., Matus S., Nassif M., Court F., Kiffin R., Martinez G., Cuervo A.M., Brown R.H., Glimcher L.H. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 2009;23:2294&#x2013;2306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758741</ArticleId><ArticleId IdType="pubmed">19762508</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M., Valenzuela V., Rojas-Rivera D., Vidal R., Matus S., Castillo K., Fuentealba Y., Kroemer G., Levine B., Hetz C. Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis. Autophagy. 2014;10:1256&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4203551</ArticleId><ArticleId IdType="pubmed">24905722</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C., Manzano R., Vaz R., Osta R., Brites D. Synaptic Failure: Focus in an Integrative View of ALS. Brain Plast. 2016;1:159&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928542</ArticleId><ArticleId IdType="pubmed">29765840</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorana F., Brambilla L., Valori C.F., Bergamaschi C., Roncoroni C., Aronica E., Volterra A., Bezzi P., Rossi D. The BH4 domain of Bcl-X(L) rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. Hum. Mol. Genet. 2012;21:826&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">22072391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D., Brambilla L., Valori C.F., Roncoroni C., Crugnola A., Yokota T., Bredesen D.E., Volterra A. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 2008;15:1691&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">18617894</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>